These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 23804426)
1. β-mannosylceramide activates type I natural killer t cells to induce tumor immunity without inducing long-term functional anergy. O'Konek JJ; Kato S; Takao S; Izhak L; Xia Z; Illarionov P; Besra GS; Terabe M; Berzofsky JA Clin Cancer Res; 2013 Aug; 19(16):4404-11. PubMed ID: 23804426 [TBL] [Abstract][Full Text] [Related]
2. Structure-Function Implications of the Ability of Monoclonal Antibodies Against α-Galactosylceramide-CD1d Complex to Recognize β-Mannosylceramide Presentation by CD1d. Clark K; Yau J; Bloom A; Wang J; Venzon DJ; Suzuki M; Pasquet L; Compton BJ; Cardell SL; Porcelli SA; Painter GF; Zajonc DM; Berzofsky JA; Terabe M Front Immunol; 2019; 10():2355. PubMed ID: 31649670 [TBL] [Abstract][Full Text] [Related]
3. Stimulation of a shorter duration in the state of anergy by an invariant natural killer T cell agonist enhances its efficiency of protection from type 1 diabetes. Tohn R; Blumenfeld H; Haeryfar SM; Veerapen N; Besra GS; Porcelli SA; Delovitch TL Clin Exp Immunol; 2011 Apr; 164(1):26-41. PubMed ID: 21361909 [TBL] [Abstract][Full Text] [Related]
4. Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy. Kharkwal SS; Johndrow CT; Veerapen N; Kharkwal H; Saavedra-Avila NA; Carreño LJ; Rothberg S; Zhang J; Garforth SJ; Jervis PJ; Zhang L; Donda A; Besra AK; Cox LR; Almo SC; Howell A; Evans EE; Zauderer M; Besra GS; Porcelli SA Cancer Res; 2021 Apr; 81(7):1788-1801. PubMed ID: 33483371 [TBL] [Abstract][Full Text] [Related]
6. Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity. O'Konek JJ; Illarionov P; Khursigara DS; Ambrosino E; Izhak L; Castillo BF; Raju R; Khalili M; Kim HY; Howell AR; Besra GS; Porcelli SA; Berzofsky JA; Terabe M J Clin Invest; 2011 Feb; 121(2):683-94. PubMed ID: 21245578 [TBL] [Abstract][Full Text] [Related]
7. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. Parekh VV; Lalani S; Kim S; Halder R; Azuma M; Yagita H; Kumar V; Wu L; Kaer LV J Immunol; 2009 Mar; 182(5):2816-26. PubMed ID: 19234176 [TBL] [Abstract][Full Text] [Related]
8. α-Galactosylceramide but not phenyl-glycolipids induced NKT cell anergy and IL-33-mediated myeloid-derived suppressor cell accumulation via upregulation of egr2/3. Huang JR; Tsai YC; Chang YJ; Wu JC; Hung JT; Lin KH; Wong CH; Yu AL J Immunol; 2014 Feb; 192(4):1972-81. PubMed ID: 24465013 [TBL] [Abstract][Full Text] [Related]
9. Non-glycosidic compounds can stimulate both human and mouse iNKT cells. Jukes JP; Gileadi U; Ghadbane H; Yu TF; Shepherd D; Cox LR; Besra GS; Cerundolo V Eur J Immunol; 2016 May; 46(5):1224-34. PubMed ID: 26873393 [TBL] [Abstract][Full Text] [Related]
10. Invariant NKT cell anergy is induced by a strong TCR-mediated signal plus co-stimulation. Iyoda T; Ushida M; Kimura Y; Minamino K; Hayuka A; Yokohata S; Ehara H; Inaba K Int Immunol; 2010 Nov; 22(11):905-13. PubMed ID: 21118907 [TBL] [Abstract][Full Text] [Related]
11. Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer. Wang Y; Bhave MS; Yagita H; Cardell SL Front Immunol; 2020; 11():581301. PubMed ID: 33193386 [TBL] [Abstract][Full Text] [Related]
12. Development of spontaneous anergy in invariant natural killer T cells in a mouse model of dyslipidemia. Braun NA; Mendez-Fernandez YV; Covarrubias R; Porcelli SA; Savage PB; Yagita H; Van Kaer L; Major AS Arterioscler Thromb Vasc Biol; 2010 Sep; 30(9):1758-65. PubMed ID: 20539017 [TBL] [Abstract][Full Text] [Related]
13. Dissociated expression of natural killer 1.1 and T-cell receptor by invariant natural killer T cells after interleukin-12 receptor and T-cell receptor signalling. Emoto M; Shimizu T; Koike H; Yoshizawa I; Hurwitz R; Kaufmann SH; Emoto Y Immunology; 2010 Jan; 129(1):62-74. PubMed ID: 20028429 [TBL] [Abstract][Full Text] [Related]
15. Activation or anergy: NKT cells are stunned by alpha-galactosylceramide. Sullivan BA; Kronenberg M J Clin Invest; 2005 Sep; 115(9):2328-9. PubMed ID: 16138189 [TBL] [Abstract][Full Text] [Related]
16. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses. Hung JT; Huang JR; Yu AL J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781 [TBL] [Abstract][Full Text] [Related]
17. The iNKT cell ligand α-GalCer prevents murine septic shock by inducing IL10-producing iNKT and B cells. Park YH; Lee SW; Kim TC; Park HJ; Van Kaer L; Hong S Front Immunol; 2024; 15():1457690. PubMed ID: 39355237 [TBL] [Abstract][Full Text] [Related]
18. Alpha-galactosylceramide pre-treatment attenuates clinical symptoms of LPS-induced acute neuroinflammation by converting pathogenic iNKT cells to anti-inflammatory iNKT10 cells in the brain. Kim TC; Park HJ; Lee SW; Park YH; Van Kaer L; Hong S Inflamm Res; 2024 Sep; 73(9):1511-1527. PubMed ID: 39028491 [TBL] [Abstract][Full Text] [Related]
19. α-Galactosylceramide treatment before allergen sensitization promotes iNKT cell-mediated induction of Treg cells, preventing Th2 cell responses in murine asthma. Chen Q; Guo X; Deng N; Liu L; Chen S; Wang A; Li R; Huang Y; Ding X; Yu H; Hu S; Nie H J Biol Chem; 2019 Apr; 294(14):5438-5455. PubMed ID: 30745361 [TBL] [Abstract][Full Text] [Related]
20. Imaging α-GalCer-Activated iNKT Cells in a Hepatic Metastatic Environment. Babes L; Shim R; Kubes P Cancer Immunol Res; 2022 Jan; 10(1):12-25. PubMed ID: 34785505 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]